Table A1.
Patient characteristics of patients from the discovery and validation cohort.
| Characteristic | Molecular Aberration | Discovery Set n = 73 | Validation Set n = 48 | ||
|---|---|---|---|---|---|
| median (range) | median (range) | ||||
| Age | 8.90 | (0.0–15.8) | 7.33 | (0.0–16.9) | |
| % leukemia blasts | 87 | (33–98) | 78.00 | (33–98) | |
| Time to relapse (months) | 9.8 | (0.6–125.5) | 20.1 | (2.1–107.0) | |
| Overall survival (months) | 26.1 | (2.6–148.5) | 37.5 | (0.1–195.8) | |
| N (%) | N (%) | ||||
| Males, n (%) | 45 | 63.4 | 30 | 62.5 | |
| Cytogenetics | Normal | 16 | 38.1 | 10 | 21.7 |
| t(8;21) | 7 | 21.9 | 2 | 4.3 | |
| MLL rearranged | 19 | 43.2 | 10 | 21.7 | |
| Abnormal 16 | 8 | 25.0 | 1 | 2.2 | |
| -7/7q- | 1 | 4.2 | 1 | 2.2 | |
| -5/5q- | 0 | 0.0 | 0 | 0.0 | |
| 8 | 2 | 8.0 | 3 | 6.5 | |
| Complex | 0 | 0.0 | 3 | 6.5 | |
| Other | 14 | 38.9 | 14 | 30.4 | |
| No data | 2 | 8.3 | 2 | 4.3 | |
| Gene mutations | FLT3/ITD | 15 | 40.5 | 7 | 24.1 |
| NPM1 | 6 | 22.2 | 2 | 6.9 | |
| CEBPA | 5 | 20.0 | 2 | 6.9 | |
| WT1 | 5 | 20.8 | 6 | 20.7 | |
| NRAS/KRAS | 15 | 44.1 | 8 | 27.6 | |
| CKIT | 9 | 32.1 | 3 | 10.3 | |
| PTPN11 | 0 | 0.0 | 1 | 3.4 | |